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Infection with the human immunodeficiency virus-1 (HIV) and the resulting acquired immune deficiency syndrome (AIDS) alter
not only cellular immune regulation but also the bone metabolism. Since cellular immunity and bone metabolism are intimately
intertwined in the osteoimmune network, it is to be expected that bonemetabolism is also affected in patients with HIV/AIDS. The
concerted evidence points convincingly toward impaired activity of osteoblasts and increased activity of osteoclasts in patients with
HIV/AIDS, leading to a significant increase in the prevalence of osteoporosis. Research attributes these outcomes in part at least to
the ART, PI, and HAART therapies endured by these patients. We review and discuss these lines of evidence from the perspective of
translational clinically relevant complex systematic reviews for comparative effectiveness analysis and evidence-based intervention
on a global scale.
1. Osteoimmunopathology in HIV & AIDS:
A Case for Fragile Bones
1.1. Osteoimmunology. Osteoimmunology pertains to the
physiological process that involves the intimate intertwining
of bone metabolism and cellular immune surveillance. It is
a novel interdisciplinary research field that has converged
into studies of the interplay between the immune system and
bone metabolism.
Osteoimmunopathology refers to the chronic or acute
inflammatory reactions subsequent to an excessive immune
response that damage bones and joints, as in osteoporosis,
or to the sequelae of bone pathologies upon regulation
of cell mediated immunity. Cytokines and other soluble
immune factors modulate and regulate the maturation
of osteoblasts responsible for bone formation, and the
osteoclastic bone resorption [1–4]. In addition, bone is
richly innervated by both autonomic and sensory neu-
rons, which serve sensory and regulatory functions, and
directly mediate bone and immune cell activities in the
neuroimmune network [5]. Moreover, present understand-
ing of the neuroendocrine-immune regulatory pathway
dictates that hormones (e.g., adrenocorticotropin hormone
[ACTH]; [6]; parathyroid hormone and calcitonin; [7–9])
play an important role in maintaining bone metabolism,
and thus contribute to bone mineralization and mass,
by directly influencing the metabolism of osteoblasts and
osteoclasts.
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The parathyroid hormone pathway is of particular note
in this context because it appears to regulate production
of the proinflammatory cytokine, interleukin (IL)-6, and
of the Receptor Activator for Nuclear Factor κ B Ligand
(RANKL) (i.e., TRANCE: Tumor Necrosis Factor- [TNF-]
related activation-induced cytokine, OPGL: Osteoprotegerin
Ligand, ODF: Osteoclast Differentiation Factor, TNFS11).
This accomplished through osteoblasts, thereby facilitating
the differentiation, activation, and survival of osteoclasts
[10, 11]. That is to say, parathyroid hormone and parathyroid
hormone-related protein (PTH-rP) promote bone resorp-
tion by regulating OPGL (i.e., RANKL), and de facto the
release of calcium [12, 13].
Estrogen deficiency results in a net bone loss as a
consequence of an increase in production of RANKL, a
decrease in production of OPGL by osteoblastic lineage cells,
and an enhancement of the secretion of pro-inflammatory
and proresorptive cytokines by lymphocytes such as IL-1,
IL-6, and TNF-α. OPGL and its binding to the OPGL
receptor located on osteoclast precursors are essential for
development and activation of osteoclasts. They are critical
regulators of physiological bone remodeling as in osteoporo-
sis. OPG receptor is another regulator protein, which binds
to RANKL, blocks RANK/RANKL interaction as a result
inhibiting maturation of osteoclast precursors to osteoclasts.
Therefore, production of OPGL by osteoblast lineage cells
and activated T cells can directly regulate osteoclastogenesis
and bone remodeling [14, 15]. OPGL is among the principal
causes of bone and cartilage destruction, as it binds to its
OPGL receptor on preosteoclastic cells, it inhibits osteoclast
maturation. In a delicate regulatory loop, the natural decoy
receptor osteoprotegerin (OPG) binds to OPGL, as well as
RANKL, and prevents bone loss by blocking RANK and
OPGL receptor activation. OPG expression is induced by
estrogen, which provides a molecular explanation of post-
menopausal osteoporosis in women due to decreased levels
of the hormone [16]. The bone protective effect of estrogen is
mediated in large part by transforming growth factor (TGF)-
β, which induces apoptosis in osteoclast cells [17, 18], thus
closing this remarkable and finely regulated balance between
bone metabolism and neuroendocrine immunoregulation.
1.2. Osteoporosis in Otherwise Normal Individuals. Osteo-
porosis develops when bone that is resorbed is not replaced
by new bone. It is the result of any imbalance in bone
turnover that causes an excess of osteoclast activity (bone
resorption) over osteoblast activity (bone formation).
Osteoporosis is a bones disease that leads to an increased
risk of fracture. It is among the most common human bone
diseases and is characterized by low bone mass or bone min-
eral density and loss of bone tissue: bone microarchitecture is
disrupted, and the amount and variety of proteins in bone is
altered. The World Health Organization (WHO) in women
defines osteoporosis as bone mineral density 2.5 standard
deviations below peak bonemass (20-year-old healthy female
average).
Osteoporosis is most common in women after meno-
pause (i.e., postmenopausal osteoporosis), but may also
develop in men or women of any age consequential to
hormonal disorders (e.g., hyperparathyroidism) and other
chronic diseases, or glucocorticoids intake (i.e., steroid- or
glucocorticoids-induced osteoporosis). Given its influence in
the risk of fragility fracture, osteoporosis may significantly
affect life expectancy and quality of life. Osteoporosis can
be prevented with lifestyle changes (e.g., exercise) and
sometimes medication (e.g., dietary supplements of calcium,
vitamin D, bisphosphonates). The RANKL/OPG ratio has
been implicated in the development and progression of
fragile bones and osteoporosis [15, 19–21].
The three main mechanisms by which osteoporosis
develop include
(1) inadequate peak bone mass (the skeleton develops
insufficient mass and strength during growth),
(2) excessive bone resorption,
(3) inadequate formation of new bone during remodel-
ing.
Interplay of these three mechanisms underlies the devel-
opment of fragile bone tissue.
1.3. “Fragile Bones” in HIV/AIDS. Early clinical observations
were made of patients infected with the human immunode-
ficiency virus-1 (HIV) and exhibiting the acquired immune
deficiencies syndrome (AIDS). A spectrum of pathologies
was found that afflicts HIV-seropositive patients as their con-
dition worsens to HIV/AIDS. These patients demonstrated
increased susceptibility to develop weak and fragile bones,
decreased bone mineralization, and increased osteoporosis
[22–24]. Nevertheless, the fundamental underlying biologi-
cal mechanisms remained elusive, until now, as the field of
osteoimmunology has become better established.
In brief, an exhaustive Cochrane systematic review
established that the clinical data taken together show that
decreased bone mineral density occurs more commonly in
patients with HIV than in the general population, making the
group of HIV-seropositive men and womenmore susceptible
to osteoporosis and consequent fragility fractures [25]. In
fact, osteoporosis in HIV-infected persons is at least as
prevalent as in postmenopausal women, despite the fact that
this population is not listed in primary care guidelines as
one that should be considered for screening [26]. This is
perhaps due to the fact that the data still fail to clearly expose
the fundamental mechanisms that underlie osteoporotic
processes in HIV/AIDS.
The role of antiretroviral therapy (ART) in the prevalence
estimates of osteopenia and osteoporosis in HIV-infected
patients was initially equivocal [27]. However, the clinical
evidence linking HIV-associated osteoporosis directly to
ART intervention appears now more clearly established
[28, 29]. (Refer to pages 10, 12, and 13 for a complete
perspective on PI/HAART/ART impact on osteoporosis.
While there is evidence in support of both the association
of PI/HAART/ART and osteoporosis, as well as the opposing
views, this paper supports the clinical evidence for the direct
link and intervention of PI/HAART/ART and osteoporosis.
For a complete perspective, opposing articles are also cited.)
By contrast, data to this date fail to demonstrate consistent
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interactive relationships among the observed ART drug-
specific effects upon clinically relevant bone mineral density
decline in these patients [28].
2. Osteoimmunopathology and Osteoporosis
2.1. Bone Metabolism. Bone metabolism consists of a com-
plex series of finely regulated steps and events, which
involve primarily the activity of bone forming osteoblasts
and bone destroying osteoclasts (Bone metabolism processes
are generally effectively equal throughout the axial and the
appendicular skeletons, although certain specific differences
exist that depend upon local epigenetic regulatory and
modulatory events (e.g., forces and stress upon the teeth
during mastication and the consequential forces upon the
alveolar bone [30, 31]).)
Osteoblasts are immature mononucleated bone-forming
cells that derive from osteoprogenitor cells as a common
family branch that arises from mesenchyme. The mes-
enchyme is a type of loose connective tissue, derived from
the three embryonic germ layers (i.e., endoderm, mesoderm,
and ectoderm). In ontogenic development, the mesodermal
middle layer gives rise to the skeleton and the hematopoietic
system [32]. Core binding factor 1 (Cbfa1) also known
as the runt-related transcription factor 2 (Runx2) and
the downstream factor osterix (Osx) are critical transcrip-
tion factors for lineage commitment of stem cells toward
osteoblast differentiation [30, 33, 34]. Although a relatively
rare event, it may be hypothesized that, given the appropriate
microenvironment, osteocytes and osteoblasts can revert
back to earlier stages of their development. Whether ART,
PI, or HAART, or more directly HIV infection may modulate
and control such a reversal is emerging as a plausible working
hypothesis.
The principal proteomic signature of osteoblasts is the
production and expression of alkaline phosphatase (EC
3.1.3.1), a key dephosphorylating enzyme that contributes to
the accumulation of calcium and phosphate into the vesicles
generated during the formation of the matrix. Four principal
isozymes of alkaline phosphatase have been recognized, and
theALPL gene is now known to be located on chromosome 1.
When alkaline phosphatase is missing, a disorder known as
hypophosphatasia arises, which manifests as hypercalcemia
and skeletal fragility [35]. It remains to be tested if ART,
PI, or HAART, HIV infection directly or indirectly, or the
manifestation of AIDS can regulate ALPL gene expression.
Osteoblasts also produce bone sialoprotein (a 60–80 kDa
small integrin-binding ligand and a member of SIBLING
proteins, a constituent of mineralized tissues such as bone,
dentin, cementum, and calcified cartilage), osteocalcin (i.e.,
BGLAP: bone gamma-carboxyglutamic acid-containing pro-
tein) and osteopontin (OPN) (i.e., BSP-1 or BNSP: bone
sialoprotein I, ETA-1: early T-lymphocyte activation, SPP1:
secreted phosphoprotein 1). OPN is produced by osteoblasts
as well as variety of immune cells, including macrophages,
neutrophils, dendritic cells, and T and B cells. In immune
metabolism, OPN is endowed with chemotactic properties
that promote cell recruitment to inflammatory sites as
well as adhesion properties to several integrin receptors,
which promote T-cell activation, cytokine production, and
regulation of apoptosis. In brief, the SIBLING protein family,
including OPN, carries complex molecular and epigenetic
regulatory roles in osteogenesis and in cellular immune
regulation [36–38].
Recent data, moreover, implicate a significant role of
OPN in the recruitment of macrophages in the central
nervous system of patients with HIV/AIDS, thus suggesting
an important role in the onset and progression of neuroAIDS
[39]. This epigenetic factor was overlooked in previous
reviews of patients with HIV/AIDS suffering from AIDS-
related neurological and neurocognitive impairments [40–
42].
OPN regulates the development of distinct effector T
cells, such as specifically TH1 and TH17 cells [43]. In
addition, OPN plays a critical role in regulating osteoclasts,
which are responsible for bone resorption. Osteoclasts
are large multinucleated cells that arise and derive from
the myeloid common progenitors and are essentially of a
parallel lineage to that of immune monocytes/macrophages.
Similar to the myeloid family, osteoclasts are endowed
with phagocytic properties, share several families of plasma
membrane receptors with certain immune cell populations,
and function in a manner similar to their mature myeloid
equivalent. Osteoclasts are found on bone surfaces in what
are called Howship’s lacunae, bone resorption pits that result
following breakdown of the bone surface and consequential
erosion of the bone by the osteoclastic enzymes, including
lysosomes, organic acids, and hydrolytic enzymes. The
osteoclastic layer that contacts the bone is divided into
the microvillus structure, a ruffled border rich in plasma
membrane folding, and a ring-like perimeter of cytoplasm,
termed the clear zone, that marks the area of bone in the
process of being resorbed.
Research has now established that unloading of stress,
such as that brought about by teeth upon the alveolar
bone, results in extensive bone remodeling. In the case of
the tooth sockets, teeth can move as a result of excessive
unloading stress in both vertical (“supereruption”) and
horizontal direction (“drift”). Animal studies show that OPN
expression is necessary for the “drift” process, but not the
“super-eruption” event. The biological mechanism begins to
become apparent, as it was observed that RANKL expression
increased significantly in the distal periodontal ligament in
the first week following unloading, and the OPN-induced
involvement of the PI3K and MEK/ERK pathway was
demonstrated in osteoclast activation following unloading-
induced drifting of teeth [44].
It has been proposed that the lateral drift imposed upon
the teeth subjected to bruxism (Bruxism refers to the events
characterized by the grinding of the teeth that typically
includes the clenching of the jaw.) stress strain created by
the oral parafunctional habit of grinding one’s teeth and
the paired activity of jaw clenching may be a significant
participatory causative agent to bone resorption of the
involved tooth socket, leading progressively to retraction of
the gum line, and exposure of the dentin inferior to the
dentin-enamel juncture [45–47]. Abfraction of the exposed
dentin follows, with increased tooth sensitivity [48], pain,
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and possible involvement of the tooth pulp.While abfraction
is still regarded by some as a theoretical concept [49],
the model, in and of itself suggests that it is possible and
even probable that the etiology and progression of this
pathological process is favored in patients with osteoporosis.
This hypothesis appears to be confirmed by the epidemiology
of abfractions, which has a significantly higher prevalence in
aging andwomen. Undoubtedly, the potential role of occlusal
loading in the loss of cervical tooth tissue is important in
the management of occlusion and must be incorporated
into a treatment plan for a patient with abfraction lesions.
This also pertains to patients with HIV/AIDS [50]. Research
must now be crafted to test the hypothesis that patients with
HIV/AIDS are at higher risk of abfractions consequentially to
their increased risk of osteoporosis, and that the underlying
osteoimmune mechanism involves OPN and RANKL activa-
tion following lateral drift in patients with HIV/AIDS who
grind.
Bruxism generally includes side-to-side grinding and is
often accompanied by jaw clenching and can be induced
by stress and anxiety during both sleep and when awake.
Together, they can lead to chronic discomfort and pain in
the head and neck region, as well as dentition, masticatory
muscle, and facial skeletal sequelae. In the more severe
cases, clenching and grinding can result in disorders of
the temporomandibular joint, which can be exacerbated by
osteoporosis by means of at least two mechanisms:
(1) osteoclastic activity of the cartilaginous corona of
the condyle may lead to bone-on-bone frictions that
engender inflammatory reactions at the joint, and
consequentially more extensive osteoclast activity
and accelerated bone resorption at the temporo-
mandibular joint, which will lead to joint disorder;
(2) stress loading on the osteoporotic alveolar bone will
alter occlusion and lead to impaired joint function.
It is possible and even probable that many patients with
periodontal disease who have alveolar bone loss nevertheless,
may retain normal occlusion. Bruxism can lead to excessive
wear that may alter occlusion; however, alveolar bone loss by
itself may not alter occlusion in all patients. Undoubtedly,
occlusion issues are not considered in all cases to be
sine qua non for temporomandibular joint disorders [51].
Temporomandibular joint disorders represent a complex
set of issues, which can involve a range of variables (e.g.,
psychoemotional stress of having HIV/AIDS, which may
lead to depressive symptoms) such as increased bruxism,
and increased tone of the masticatory musculature, which
remains in need of further study in health subjects, as well
as in patients with HIV/AIDS.
Furthermore, it is important to note that the prevalence
of temporomandibular joint disorders is significantly higher
in young adult women than in men: generally, a 2 : 1-fold
increase in prevalence is reported. Although, some reports
indicate that women might be up to 5 times more prone to
temporomandibular joint disorders than men, matched for
age. Over 80%of the patients treated for temporomandibular
joint disorders are women [52–56].
In women, the severity of symptoms is related to the age
of the patients. Pain onset tends to occur after puberty, and
peaks in the reproductive years, with the highest prevalence
occurring in women aged 20–40, and dampens in the
elderly [52–54]. The putative role of estrogen for temporo-
mandibular joint disorders in women [53]may havemultiple
mechanisms, including influencing cellular events in bone
metabolism (vide supra), as well as regulatory processes of
neuralgia, myalgias, migraines, and localized or generalized
pain responses [52, 56]. Hormone-replacement therapy has
been reported to raise the prevalence of temporomandibular
joint disorders in aging postmenopausal women, although
this observation has not been confirmed [55].
At the molecular level, recent data suggest involvement of
bone cell estrogen receptors, whereas the precise mechanism
of the osteoprotective estrogen action remains unclear. The
inhibitory action of estrogen on bone resorption appears to
be mediated by the osteoclastic nuclear estrogen receptor-α
(aka, nuclear receptor subfamily 3, group A, member 1, and
NR3A1), which directs a shortened lifespan of osteoclasts
[57]. Related findings indicate that estrogen and glucocor-
ticoids modulate the functional differentiation of osteoblasts
differentiation that is regulated by bone morphogenic pro-
teins (BMP’s) and TNF-α. BMP-2 specifically increases the
binding affinity of estrogen and glucocorticoid receptors,
thus amplifying these outcomes. By contrast, estrogens and
glucocorticoids differentially regulate the BMP-2-induced
Smad1/5/8 phosphorylation and TNF-α signaling pathways,
which participate in the regulation of target gene expression
[58].
Temporomandibular joint disorders are not observed as
a routine clinical feature in patients with HIV/AIDS. In
addition, osteoporosis generally is regarded as a condition
with high risk of developing temporomandibular joint
disorders. However, the prevalence of HIV/AIDS in women
of childbearing age is fast rising worldwide. Moreover,
and as noted above, the diagnosis of HIV/AIDS often
triggers serious symptoms of depression, which may require
treatment protocols with antidepressants, including selec-
tive serotonin reuptake inhibitors (SSRI’s). Clinically, these
pharmacotherapeutic modes of intervention are significantly
correlated not only with increased bone fragility (clinical
fragility fracture hazard rate, 2.1; CI95 : 1.3–3.4 (vide infra)
[59], but also with clinically relevant increased clenching of
the jaw and bruxism. It was proposed that SSRI-induced
bruxism may actually manifest a form of SSRI-induced
akathisia, involving centrally somatodendritic receptors on
the cell bodies of raphe´ serotonergic neurons that project to
the ventral tegmental area of the midbrain, and modulate the
firing of the mesocortical tract from the ventral tegmental
area to the prefrontal cortex for regulating masticatory
muscle activity [60].
SSRI-induced bruxism [61] may lead to potential impor-
tant microtrauma of the temporomandibular joint. This
can be manifested pathologically in variety of ways, from
thinning of the synovial temporomandibular joint disc that
can lead to its perforation and result in bone-on-bone
rubbing with crepitus or osteoarthrosis, to intrusion of
the posterior molars and back-sliding of the front incisor
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and canine teeth to occlude on the posteriors teeth, with
consequential posteriorization of the jaw and displacement
of temporomandibular joint disc and increased risk for
onset of an arthritic process at the temporomandibular joint.
Animal studies confirm that depression induces bone loss,
and therefore favor osteoporosis by means of a mechanism
mediated by brain-to-bone sympathetic signaling. Whereas
these effects can be alleviated by increasing central serotonin,
the negative skeletal effects of the peripheral SSRI-induced
increase in serotonin per se outweigh the osteoimmune
benefits resulting from the enhanced central serotonin
antidepressant and antisympathetic activity [62].
Therefore, these lines of evidence lead us to propose
the hypothesis that the pathological condition of temporo-
mandibular joint disorder and its sequelae are more prevalent
than one might expect in patients with HIV/AIDS because
of their related osteoimmunopathology. The probability that
men and women with HIV/AIDS suffer from temporo-
mandibular joint disorders with an incidence significantly
greater than epidemiological statistics would presently sug-
gest is clinically relevant. In many patients with disorders of
the temporomandibular joint, the auriculotemporal nerve,
a branch of the 2nd branch of the trigeminal cranial nerve
(CV-II, maxillary branch), may be compressed, irritated,
or otherwise damaged. This results in significant central
and peripheral nerves via the gasserian ganglion and other
central pathways, in precipitating a series of pathological
manifestations reminiscent of a spectrum of neurological
pathologies [63]. The need emerges, therefore, to construct
clinical studies aimed at the clinical involvement of tem-
poromandibular joint disorders in HIV/AIDS pathologies,
and experimental studies directed at testing the putative
involvement of the gasserian ganglion in neuroAIDS.
2.2. Immune Modulators of Bone Metabolism. Immune cells
from the lymphoid and the myeloid lineages influence bone
remodeling by exerting an impact on osteoclastogenesis.
Activated T cells play a critical role in bone loss consequential
to immunopathology associated with systemic viral infec-
tions, such as HIV, as well as chronic local bone and joint
diseases, such as rheumatoid arthritis or inflammatory bowel
disease. Similarly, and true to homeostatic regulation, T cells
can be regulatory and even inhibitory of these bone forming
or removing events [64–69].
Based on these observations, and on the present under-
standing of the immunopathology of HIV/AIDS, it is not
unreasonable to expect, therefore, a complex and varied
series of osteoimmunopathologies in asymptomatic HIV-
seropositive patients, as well as in patients with fully
developedmanifestations of AIDS. For instance, the Immune
Reconstitution Inflammatory Syndrome (IRIS) is often a
considerable problem in the treatment of patients with
HIV/AIDS. IRIS is characterized by highly elaborate and
significant activation of both innate and adaptive immune
responses with elevation of body fluid chemokines and
cytokines, including commonmarkers of inflammation such
as C-reactive protein, interferon-inducible protein 10, and
IFN-γ, and that together signify innate and adaptive immune
activation [70].
IRIS-responding HIV-seropositive patients show higher
frequencies of effector memory T cells positive for pro-
grammed death (PD)-1, a member of the extended CD28/
CTLA-4 family of T-cell regulators, HLA-DR+, and Ki67+ in
CD4+T, and in regulatory T CD4+CD25+FoxP3+ cells, than
IRIS-nonresponding otherwise matched HIV-seropositive
patients. The PD-1+CD4+ T cells in the IRIS-responding
patients express increased levels of LAG-3, CTLA-4, and
ICOS, and are driven to a TH1/TH17 cytokine profile when
stimulated in vitro. Plasma levels of IRIS-responding HIV-
seropositive patients also show marked elevation in the TH1
cytokine IFN-γ as well as in IL-7, which together confirms
that IRIS is predominantly CD4-mediated phenomenon
directed at reconstituting efficacious activation of effector
and regulatory T cells [71].
Of course, reconstitution of T-cell-mediated immunity is
desirable in patients with HIV/AIDS, but overreconstitution
of T-cell responses into a pronounced, unrestricted, and
uncontrollable immune reconstitution inflammatory syn-
drome is less desirable. Here, we propose the hypothesis
that, based upon our current understanding of osteoimmune
interactions and of the incipient osteoimmunopathology in
patients with HIV/AIDS, including increased bone fragility
and decreased compact bone mineralization together, IRIS
may actually dangerously increase the relative prevalence of
osteoporosis in patients with HIV/AIDS.
We propose that one mechanism by which IRIS may
induce osteoporosis in these patients is bymeans of increased
TH17 activity. Lymphocytes expressing γδ T-cell receptors
constitute an entire system of functionally specialized subsets
that have been implicated in the regulation of immune
responses, including responses to pathogens and allergens,
and in tissue repair. γδ T cells represent a small sub-
population of T cells that, unlike αβ T cells, function
more as cells of the innate immune system. γδ T cells
are known to mediate the production of inflammatory
cytokines, including interferon-γ, tumor necrosis factor-α,
and interleukin (IL)-17 (i.e., TH17 cells) and thus enable the
activation of other subsets of infiltrating effector cells. It is
important to note, again perhaps in reference to neuroAIDS,
that IL-17 and its receptor IL-17R have been implicated in
the pathogenesis of immune-mediated CNS diseases [72].
Immune cells that are endowed with the ability to
respond to challenges by means of IL-17 are in fact respon-
sible for a wide variety of inflammatory and autoimmune
disorders. Data demonstrate the presence of certain TH17
that are also capable of producing IFNγ, indicating a
putatively overlapping subpopulation of TH17/TH1 cells
[73, 74]. In brief, TH17 cells are characterized by sur-
face expression of CCR6, IL-23R, IL-12Rb2, and CD161,
expression of T-bet, the retinoic acid-related orphan receptor
(ROR)γτ. As noted, they have the ability to produce
IFN-γ and IL-17A in the presence of IL-12 and to arise
from CD161+CD4+ precursors, which constitutively express
RORγτ and IL-23R, in response to the combined activity
of IL-1β and IL-23. Whereas they generally are unre-
sponsive to TGF-β for mediation of differentiation, they
can favor their proliferation by inhibiting T-bet expression
[74].
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The IL-17 family of cytokines includes IL-17B, IL-17C,
IL-17D, IL-17E (also called IL-25), and IL-17F. The primary
function of IL-17-related cytokines is to modulate induction
of many immune signaling molecules. The most notable role
of IL-17 is its involvement in inducing and mediating proin-
flammatory responses and is commonly associated with
allergic responses. IL-17 induces the production of many
other cytokines (such as IL-6, G-CSF, GM-CSF, IL-1β, TGF-
β, TNF-α), chemokines (including IL-8, growth related gene
alpha, GRO-α, and MCP-1), and prostaglandins (e.g., PGE2)
from many cell types (fibroblasts, endothelial cells, epithelial
cells, keratinocytes, and macrophages). As a result, the IL-
17 family has been linked to many immune/autoimmune-
related diseases including osteoimmunopathologies such
as rheumatoid arthritis and osteoporosis, which involve
activation of osteoclastic bone resorption activity [31].
Each member of the IL-17 family has a distinct pattern
of cellular expression. The expression of IL-17A and IL-17F
is restricted to a small group of activated T cells and is
upregulated during inflammation. IL-17B is expressed in
several peripheral tissues and immune tissues. IL-17C is
also found to be upregulated in inflammatory conditions,
although in resting conditions it is low in abundance.
IL-17D is highly expressed in the nervous system and in
skeletal muscle and IL-17E is found at low levels in various
peripheral tissues [75–77].
Although it has only limited homology to other
cytokines, IL-17 exhibits pro-inflammatory properties sim-
ilar to those of TNFα, particularly with respect to induc-
tion of other inflammatory effectors, including several
bone pathologies, most notably rheumatoid arthritis [78].
Research has established that signal transduction pathways
dependent on PI3K/Akt and NF-κB are involved in bone-
related pathology-mediated IL-17 possibly by modulating,
in part at least, production of related pro-inflammatory
cytokines (i.e., IL-6, IL-8) by synovial fibroblasts [79].
The IL-17 receptor family consists of five, broadly
distributed receptors that present with individual ligand
specificities. Within this family of receptors, IL-17R is
the best described. IL-17R binds both IL-17A and IL-17F
and is expressed in multiple tissues: vascular endothelial
cells, peripheral T cells, B-cell lineages, fibroblast, lung,
myelomonocytic cells, and marrow stromal cells. IL-17RB
binds both IL-17B and IL-17E. Furthermore, it is expressed
in the kidney, pancreas, liver, brain, and intestine. IL-17RC
is expressed by the prostate, cartilage, kidney, liver, heart,
and muscle tissues. The IL-17RC gene may undergo alternate
splicing to produce a soluble receptor in addition to its
cell membrane-bound form. In similar manner, the gene
for IL-17RD may undergo alternative splicing to yield a
soluble receptor. This feature may allow these receptors to
inhibit the stimulatory effects of their yet-undefined ligands.
The least described of these receptors, IL-17RE, is known
to be expressed in the pancreas, brain, prostate, and bone
[75–78].
In patients with HIV/AIDS, the role of TH17 cells and
IL-17 have been under active investigation for some years
[80], and the fine regulation of the TH17/Tregs ratio is now
recognized as a critical predictor of HIV/AIDS pathogenesis
[81], and Th17 populations are depleted in animal models of
HIV infection and progression to AIDS [82].
2.3. Osteoporosis in Patients with HIV/AIDS. Taken together,
the experimental evidence to date suggests that it is possible
and even probable that patients with HIV/AIDS may be
at increased risk for osteoporosis. Indeed, the clinical data
appears to support this inference.
A recent modeling study defined and characterized the
progression of low bone mineral density patients with
HIV/AIDS. Predictive analyses based on linear regression
and logistic polyatomic regression using in the polytomous
model the categorical ranking of disease progression and
severity were conducted on a longitudinal cohort sample
of 671 patients. Clinical outcome measures consisted of
repeated dual-energy X-ray absorptiometry scans, which
yielded accurate estimates of bone mineral density, over 2-
3 years. The prevalence of decreased bone mineral density
in the sample was 47.5%, and the prevalence of osteo-
porosis was 23%. Clinically relevant progression to bone
demineralization was observed in 28% of the patients, and
15.6% of the patients progressed to osteoporosis during
study period. Statistically significant and clinically relevant
predictors of these patterns of progression were age (odds
Ratio (OR) : 1.07; CI95 = 1.05–1.08 (P < .0001), gender
(male), OR : 2.23; CI95 = 1.77–2.8 (P < .0001), cachexia
and wasting syndrome), OR : 1.14; CI95 = 1.11–1.17 (P <
.0001), duration of treatment with protease inhibitor (PI),
(OR : 1.18; CI95 = 1.12–1.24 (P < .0001), or with antiviral
reverse transcriptase inhibitor (ART, tenofovir), (OR = 1.08;
CI95 = 1.03–1.14 (P < .0019), and current PI treatment
(OR : 1.64; CI95 = 1.35–2.04 (P < .0001) [83].
These findings were replicated in a cohort of 33 young
men (mean age 38 ± 9) with HIV/AIDS (mean plasma
HIV RNA: 5.0 ± 1.2 log10 copies/ml, and matched for
body mass index (mean: 22.7 ± 3.3)). The cohort was
followed longitudinally with a regular dual-energy X-ray
absorptiometry of the lumbar spine, femoral neck, and
total hip, and with clinical assessments for osteopenia and
osteoporosis, defined by WHO criteria as T-scores between
−1 and −2.5 and −2.5 or less, respectively. The data
confirmed that the prevalence of low bone mineral density
and elevated osteoporosis in young men with primary HIV
infection was predicted by increasing age, HIV viremia, lower
body mass index, and introduced an intriguing new variable:
thyroid stimulating hormone levels [84].
In an earlier study, polytomous logistic regression also
showed the significant predictive strength of age, homosexual
transmission, low body mass index, and HIV plasma viral
load for onset of bone abnormalities, defined in that study as
decreased bone mineral density and increased osteoporosis
and bone fragility, in men with HIV/AIDS. This study also
showed older age, and low CD4 lymphocyte count nadirs
were independently associated with osteoporosis in women
with HIV/AIDS. However, the analysis failed to show the
predictive strength of HAART for osteoporosis in these two
groups, following adjustment and stratification for the con-
sidered anthropometric parameters [85]. That finding con-
firmed an earlier study with a Slovenian cohort of HIV/AIDS
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patients, in which the increased prevalence of osteoporosis
was confirmed in a range similar to that reported by others
(i.e., osteopenia: 47%, osteoporosis: 12%), but ART, PI, or
HAART were not found to be significant predictors for
these clinical outcomes [86] (Refer to pages 3, 12, and 13
for a complete perspective on PI/HAART/ART impact on
osteoporosis. While there is evidence in support of both the
association of PI/HAART/ART and osteopororis, as well as
the opposing, this paper supports the clinical evidence for the
direct link and intervention of PI/HAART/ART and osteo-
pororis. However, for a full and thorough perspective of the
case, articles in opposition of this connection are also cited.)
It seems clear that the clinical data support the inference
that based on our current understanding of osteoimmunol-
ogy, patients with HIV/AIDS are expected to have increased
prevalence of osteoimmunopathologies, including in partic-
ular osteoporosis. Increased methodological stringency and
internal validity constraints will be required in future studies
to establish beyond doubt the predictive role of ART, PI, and
HAART for osteoporosis in patients with HIV/AIDS.
3. Evidence-Based Practice
for Osteoimmunopathology in
HIV/AIDS: Osteoporosis
3.1. Treating Osteoporosis in Non-HIV/AIDS Patients. In
the context of osteoporosis in patients who do not have
HIV/AIDS, most treatments have some proven efficacy in
reducing the risk of vertebral fractures. Overall however, the
evidence is less convincing in terms of the prevention of
nonvertebral fractures, in part because available randomized
control trials (RCT’s) typically yield post hoc subgroup
analyses, rather than analyses based on the intent-to-treat.
The intention-to-treat analysis aims to circumvent the effects
of crossover and dropout, which alter the randomization
to the treatment groups, and thus yield spurious data. In
principle, the intention-to-treat analysis seeks to describe
the potential effects of treatment policy rather than on the
potential effects of a specific treatment, because it is a means
of analyzing the outcome of a RCT based on the initial
treatment intent, not on the treatment eventually adminis-
tered. For the purposes of the intention-to-treat analysis, the
entire sample that begins the treatment is considered to be
part of the trial, whether they finish it or not [87]. In most
recent development of this critical concept, the “modified
intention to treat” (mITT) approach was proposed to
provide some degree of internal control to sampling and
sample allocation concerns consequential to the inclusion
and the exclusions criteria imposed in a carefully crafted RCT
[88].
A meta-analysis of eleven RCT’s-Phase III was performed
to compare the relative risks of nonvertebral antifracture
efficacy for at least 3 years, confirmed by radiographs,
of bisphosphonates, alendronate, and risedronate among
several osteoporosis therapies in post-menopausal women.
The research synthesis emphasized stringent assessment
of the intention-to-treat sample. The analysis outcome
established significant reductions in the relative risk of
non-vertebral fracture for both alendronate (relative risk,
RR = 0.86, CI95 : 0.76–0.97, P = .012) and risedronate (RR =
0.81, CI95 : 0.71–0.92, P = .001). Risedronate and strontium
ranelate further evinced clinically relevant non-vertebral
anti-fracture efficacy in the context of this research synthesis
[89].
To further test and establish the strength of the clin-
ical recommendations and the cost-effectiveness of selec-
tive estrogen receptor modulators, bisphosphonates, and
parathyroid hormone for the prevention and in the treat-
ment of osteoporosis, a systematic review was brought
forward with the specific goal of contributing to the
body of knowledge aimed at preventing or reducing of
osteoporotic fractures in postmenopausal women. The pro-
cess of research synthesis emphasized meta-analysis, rather
than the complete traditional systematic review structure.
Studies were included in a random effect model meta-
analysis, if the outcome of fracture incidence was reported
in terms of the number of patients suffering fractures.
The clinical decision-making model was derived from the
meta-analytical results and inference to estimate the cost-
effectiveness of osteoporosis interventions by calculating the
number of fractures that occurred, as a function of the costs
associated with the osteoporotic fractures, and the quality-
adjusted life years. As a reference control, the conditions of
breast cancer and coronary heart disease were modeled by
the same approach because certain interventions can affect
the risk probabilities for these conditions. Using a sample size
of ninety RCT’s that met the inclusion criteria, a comparison
of five interventions (alendronate, etidronate, risedronate,
raloxifene, and teriparatide) to five reference control treat-
ments (calcium, calcium plus vitamin D, calcitriol, hormone
replacement therapy, and exercise), and to a no-treatment
placebo controls was possible. The intervention costs of
treating all osteoporotic women for 5 years with alendronate,
etidronate, risedronate, or raloxifene was elevated, and
the cost adjusted per quality-adjusted life years decreased
dramatically with age. In fact, of the five tested interventions,
only raloxifene appeared to reduce the risk of vertebral
fracture in postmenopausal women, independently for low
bone mineral density. However, the evidence indicated that
none of the five interventions effectively reduces the risk
of non-vertebral fracture in women, regardless of low bone
mineral density, whereas they all led to substantial gains in
quality-adjusted life-years, particularly among older women.
The research synthesis also clearly evinced that the estimated
costs varied widely across the interventions, age, and clinical
profile (i.e., prior fracture) [90].
Research synthesis, followed by a Markov model of
decision analytic techniques, was utilized to establish the
comparative effectiveness and long-term costs and out-
comes of five treatment and secondary prevention strategies
for osteoporosis: placebo, “no intervention”, alendronate,
etidronate, risedronate, and raloxifene, in postmenopausal
(65+ year old) osteoporotic women without prior fracture.
Probabilistic sensitivity analysis, which is directed at predict-
ing how changes in a givenmodel inputs can probabilistically
influence the outputs with the purpose of determining
“good practice” [91], was used to incorporate the impact of
parameter uncertainty. In addition, deterministic sensitivity
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analysis, which differs from the former in that it seeks
to predict how changes in a given model inputs can be
determined by certain specified variables to influence the
outputs, was used to compare alternative patient populations
and modeling assumptions. Life years and Quality Adjusted
Life Years were the outcomes of interest in the comparative
effectiveness investigation, which established that risedronate
was less effective than etidronate and alendronate. Alen-
dronate and etidronate were as cost-effective alternatives for
treating women with osteoporosis, although the model did
not permit long-term projection [92].
A related research synthesis confirmed these findings,
as it examined the cost-effectiveness of nonfracture side
effects of osteoporosis treatments in women screened for
osteoporosis at age 65, and treated osteoporotic subjects as
recommended with hormone replacement therapy, ralox-
ifene, or alendronate. This approach utilized the Markov
model of osteoporosis disease progression to simulate costs
and outcomes by means of calculations of incremental cost-
effectiveness ratios of screen-and-treat strategies, relative
to a no-screen and no-treat strategy. Disease progression
parameters, as well as cost and quality-of-life parameters
were outcomes of interest in this analysis. Results showed
that screening and treatment with hormone replacement
therapy act in concert to increase costs and to lower
quality-adjusted life years, relative to the no-screen, no-treat
strategy, except when the model includes the assumption
of no fracture and thus no drug-related health effects. In
conclusion, whereas raloxifene further increases costs and
quality-adjusted life years, alendronate emerges from this
research synthesis as the most cost-effective strategy relative
to the no-screen, no-treat strategy: in fact, with a fairly good
and acceptable cost-effectiveness ratio [93].
Fragility fractures cause significant morbidity and mor-
tality. Effective osteoporosis treatment can reduce fracture
incidence, but it is not known whether it is efficacious
as well in reducing mortality. A research synthesis pro-
tocol was designed with the aim of determining whether
effective osteoporosis treatment might be efficacious in
reducing mortality. Two databases (i.e., Pubmed-MEDLINE,
Cochrane Central Register of Trials), as well as some
“gray” literature obtained from American Society for Bone
and Mineral Research conference abstracts were consulted.
Eligible RCT’s were included if they established efficacy
interventions other than estrogen and selective estrogen
receptor modulators in preventing both vertebral and non-
vertebral fractures over a study duration longer than 12
months. Studies (n = 8) of risedronate, strontium ranelate,
zoledronic acid, and denosumab were included in the
research synthesis. The consensus statement arising from
the analysis was that treatment is efficacious in leading to
a reduction in mortality (relative risk analysis I = 0.89,
CI95 : 0.80–0.99, P = .036; relative risk analysis II = 0.90;
CI95 : 0.81–1.0, P = .044), and that mortality reduction is
independent from age or incidence of hip or other non-
vertebral fracture. Treatment overall was actually all the
more efficacious in reducing mortality among the older,
frailer individuals with osteoporosis at high risk of fracture
[94].
In a study aimed to review the pharmacology, phar-
macokinetics, pharmacodynamics, safety, efficacy, and use
of denosumab in osteoporosis, breast cancer, prostate
cancer, and multiple myeloma, pertinent research papers
and abstracts were identified through a complete search
of the two specific databases, Pubmed-MEDLINE and
International Pharmaceutical Abstracts, for the publications
between 1966 and July 2009. Key search terms included
denosumab, its former name AMG-162 and its trade name
Prolia, as well as its recognized functional characteristics
as a fully human monoclonal antibody that specifically
targets the receptor activator of the nuclear factor-κB ligand
(RANKL) system. Indeed, the FDA has given priority review
status to the RANKL inhibitor denosumab (Prolia) to
reduce skeletal-related events in cancer. For this particular
systematic review, all available human clinical studies were
included, except for studies in rheumatoid arthritis and
giant cell tumor of the bone. The research synthesis design
evinced that in patients with osteoporosis, denosumab
significantly reduced bone resorption and consequential
fractures, in large part by increasing bone mineral den-
sity and reducing bone turnover markers of osteoclast-
mediated function. Comparative effectiveness analysis deter-
mined that denosumab was at least as effective in reducing
bone turnover markers as intravenous bisphosphonates in
oncology patients. Efficacy analysis also established that
patients with osteoporosis commonly reported side effects
of denosumab as arthralgia, nasopharyngitis, back pain, and
headache. By contrast, the most common adverse effects
of denosumab intervention in patients with cancer were
infection, often severe enough to require hospitalization,
arthralgia, bone pain, and fatigue [95].
3.2. Patients with HIV/AIDS. Taken together, this research is
particularly timely and critical to the HIV/AIDS pandemics.
As noted above, HIV-seropositive adult men and women
suffer from severely decreased bone mineral density and
increased risk of osteoporosis-related fragility fractures. Data
indicate that the prevalence of osteoporosis in HIV-infected
individuals is more than three times greater compared
with HIV-seronegative control subjects. As noted above,
HIV+ patients treated with antiretroviral therapy (ART)
or protease inhibitors (PI) evince an even higher preva-
lence of reduced bone mineral density and increased risk
of osteoporosis, compared with their respective controls.
This evidence was reviewed in a research synthesis design
involving a random effect meta-analysis. The search of the
available evidence was broad and included the MEDLINE,
Pubmed, and EMBASE databases for peer-reviewed cross-
sectional studies between January 1966 and November
2005. The PICO criteria included pooled odds ratios of
reduced bone mineral density and increased osteoporosis,
as outcomes: the following patient population groups: HIV-
positive versus HIV-negative; the following comparative
interventions: ART-treatment versus ART-naı¨ve, and PI-
treatment versus PI-untreated. The twenty studies that met
all of the inclusion/exclusion criteria yielded 884 HIV-
seropositive patients, with a prevalence of decreased bone
density of 67% (pooled odds ratio [OR] : 6.4), of whom 15%
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manifested clinical signs of osteoporosis (pooled OR : 3.7),
compared to control HIV-seronegative subjects (n = 654).
Whereas studies did generally not correct for HIV/AIDS
severity and treatment dose, regimen and duration, the data
revealed that, compared with ART-naive patients (n = 202,
10 studies), ART-treated HIV-seropositive patients (n = 824)
showed a 2.5-fold increased odds of decreased bone mineral
density, and increased risk for osteoporosis (7 studies).
Similarly, PI-treatment increased the overall risk for lower
bone mineral density and greater risk of osteoporosis in
HIV-seropositive patients [27] (Refer to pages 3, 10, and
12 for a complete perspective on PI/HAART/ART impact
on osteoporosis. While there is evidence in support of both
the association of PI/HAART/ART and osteoporosis, as well
as the opposing, this paper supports the clinical evidence
for the direct link and intervention of PI/HAART/ART and
osteoporosis. However, for a full and thorough perspective
of the case, articles in opposition of this connection are also
cited.)
In a Cochrane systematic review, the effects of inter-
ventions aimed at increasing bone mineral density in HIV-
infected adults were examined. Following a remarkable
extensive search of the available evidence that included
MEDLINE, EMBASE, LILACS, and The Cochrane Library as
well as “gray literature such as Meeting Abstracts, AIDSTRI-
ALS, ACTIS, Current Controlled Trials, National Institutes
of Health Clinical Trials Registry, and CenterWatch, only
randomized trials that compared pharmacological or non-
pharmacological therapy with placebo, no treatment, or an
alternative therapy, in seropositive men and women 18 years
of age or older were included. The clinical outcome of inter-
est was increasing bone mineral density. The extensive and
focused nature of the systematic review yielded three RCT
studies that reported examination of the role of alendronate
in patients with HIV and osteopenia or osteoporosis. Ameta-
analysis was precluded because of excessive heterogeneity
(P < .0001), which was attributable to marked differences
in the study populations and interventions. Nonetheless,
the sensitivity analysis showed that in two homogeneous
studies (heterogeneity, P = .11), alendronate, calcium, and
vitamin D markedly improved lumbar bone mineral density
after one year, when compared with calcium and vitamin
D alone (weighted mean difference: +2.65; CI95 = 0.80–
4.51). Of note is the clinically relevant observation that
the alendronate-supplemented group did not evidence fewer
fragility fractures (relative risk [RR] : 1.28; CI95 = 0.20–8.21),
or osteoporosis symptomatology (RR : 0.50; CI95 = 0.24–
1.01), and, overall, adverse occurrence of clinical outcomes
was not significantly different between groups (RR : 1.28;
CI95 = 0.20–8.21). One RTC, markedly heterogeneous with
the others, demonstrated that patients with AIDS wasting
showed clinically important improvement in lumbar bone
mineral density following three months of testosterone
enanthate treatment, compared to placebo, (weighted mean
difference: +3.70; CI95 = 0.48–6.92), whereas progressive
resistance training failed to improve this outcome in the
patients. Neither the testosterone nor the resistance-training
group suffered adverse effects. Taken together, and as briefly
outlined above, the best available evidence that has emerged
from this systematic review confirmed that bisphosphonate
therapy in HIV-seropositive adults, and testosterone in
patients with AIDS wasting syndrome appears to be both
safe and possibly effective to improve bone mineral density.
Clearly, these conclusions are preliminary due to the limited
number of pertinent and homogeneous studies included in
this analysis [25]. Evidently,, the question remains unan-
swered as to the clinical efficacy and effectiveness of alternate
interventions, such as estrogen, testosterone, calcitonin, and
teriparatide, which are less studied in HIV-seropositive
patients.
3.3. Conclusion: Toward Comparative Effectiveness-Efficacy
Research and Analysis For Practice (CEERAP): A New Frontier.
Research to date indicates that osteoporosis is one clinically
relevant pathology in patients with HIV/AIDS, and that our
treatment armamentarium proposes several medications to
treat this condition, depending on age and gender of the
patient, severity of the HIV/AIDS pathology, and PI, ART, or
HAART course of treatment. However, the problem remains
as to what degree can the presently available lines of evidence
be taken as concerted and confluent, rather than contrasting
and contradictory. In several instances, research seeks to
demonstrate that a given treatment modality “works” in
arresting the bone resorption process, that is, the research
evidence proffers and supports the efficacy of the interven-
tion. Alternatively, research evidence may seek to emphasize
cost-effectiveness and benefit-risk ratio effectiveness.
Thus, the body of studies outlined above can be loosely
classified as either seeking to compare the efficacy of the
treatment intervention for immediate utility in practice,
or to compare the effectiveness of the modality in terms
of potential costs incurred, benefits received, with possible
exposure to risks (e.g., treatment of osteoporosis with
bisphosphonates may be efficacious, that is, “it works”, in
arresting bone resorption, but its effectiveness in terms
of the increased risk of osteonecrosis, particularly of the
mandibular and to some lesser extent of the maxillary bones,
may be prohibitive.
The search for the best available evidence for efficacious
and effective treatment intervention is a concerted effort by
the research community to translate statistical significance
data obtained in group comparisons yielded by RCT’s
and observational studies into clinically relevant consensus
revisions of practice guidelines [96]. This is the fundamental
outcome obtained by research synthesis, that is, the process
of obtaining the entire body of available research evidence
that pertains to a given patient population (here of interest:
patients with HIV/AIDS and clinical signs of osteoporosis),
treatment interventions that the clinician might consider,
and thus of which a comparison is necessary in terms
of efficacy or effectiveness, for a given clinical outcome
of interest, within a set timeframe and a given clinical
and socioenvironmental setting. Hence, the acronym of the
research question of the research synthesis process is posed
as P-I-C-O-T-S [31].
As in any cogently planned and conducted research, the
scientific process, in this case the PICOTS question, can be
simply the fundamental hypothesis of the study. Therefore,
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for the research synthesis to yield the best available evidence
is a hypothesis-driven process by which the identified
available body of evidence that pertains to the PICOTS
question is analyzed for the level and the quality of the
evidence through quantifiable means. This approach per-
mits statistical inferences based upon acceptable sampling,
heterogeneity analysis, and meta-analysis In this manner,
research synthesis leads to the articulation of an analysis of
the consensus of the best available evidence, which serves
the clinician for clinically relevant efficacy and effectiveness
decisions.
In brief, the process outlined in the preceding paragraphs
is a hypothesis-driven systematic search for the consensus of
the best available evidence for treatment. It yields a system-
atic research synthesis of comparative effectiveness and of
comparative efficacy, the cogent analysis of which converges
in patient-centered and patient-optimized evidence-based
practice. It often involves the synthesis of primary research
(RCT’s, observational studies) to yield technical research
synthesis reports, which are referred to as “systematic
reviews”. Increasingly, research synthesis protocols involve
the systematic evaluation of multiple existing systematic
reviews, a process which must not remain purely technical
but must strive to establish the clinical relevance of the
consensus evidence: hence, the term “clinically relevant
complex systematic review” [97].
Systematic reviews and clinically relevant complex sys-
tematic reviews are used in research and analysis com-
paring either the effectiveness or the efficacy of treatment
intervention. However, the “real world” of patient care
and practice demands that comparative effectiveness and
comparative efficacy research not be distinct, but in fact
remain conjoined for the ultimate administration of the best
treatment intervention in terms of what works, and of what
is most cost-effective, beneficial, and poses the least amount
of risk to the patient. Research synthesis in health care must
focus on quantifying the quality of the evidence and the
strength of the clinical recommendations, in a manner to
our expansion of the GRADE assessment tool (Phi et al.,
manuscript in preparation). Hence, we propose that the new
frontier in the domain of research synthesis in health care
will be the integration of these two traditionally distinct
avenues into a novel perspective, which could be termed
Comparative Effectiveness-Efficacy Research & Analysis for
Practice (CEERAP).
In conclusion, it is clear that HIV/AIDS has posed a
challenge to fundamental and clinical research for decades.
Surely, this is so in large part because the term actually
implies to at least three distinct epidemiologies: in the
Western societies, we note a substantial difference between
patients with HIV/AIDS in the population of multidrug
users and patients who have contracted HIV/AIDS following
unsafe sexual practices. There may be some degree of
overlap between these groups in some instances, but mostly
they represent two distinct patient populations from the
socioeconomical viewpoint. In emerging societies and in
the developing world, the HIV/AIDS epidemic is different
altogether, as it affects the pediatric population in greater
number, it is more prominent, and causes considerably
more deaths than in the West. In the heart of Africa, entire
villages may be affected, a large majority of the population
of certain countries (e.g., Swaziland) may be affected with
osteoimmune and other HIV/AIDS pathologies, which calls
for an even greater urgency for a globalization of CEERAP
(g-CEERAP).
The success of our intervention efforts to combat and
defeat HIV/AIDS worldwide in the next decade will rest on
g-CEERAP, we contend, along three principal domains:
(a) identification of the best available evidence for effec-
tiveness and efficacy of treatment intervention for
osteoporosis as a pathology of HIV/AIDS,
(b) dissemination in order to increase health literacy of
the patient and caregiver populations, as well as the
health care providers who may not be familiar with
CEER analysis for practice,
(c) worldwide access via 2G or 3G to paperless CEERAP
recommendations for full coverage of human infor-
mation technology.
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